Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Comment by DrHolidayon Jun 25, 2018 6:36pm
166 Views
Post# 28226862

RE:107,180,807 million shares traded since June 18

RE:107,180,807 million shares traded since June 18 This means that almost 54 million shares were traded over this 14.4 cent average.
The outstanding float is 84 million. So, it looks like many who bought low sold on the strength of this spike and are either out of the stock completely, or have repurchased to buy the dip on the swing trade low and now hold more than they did before.

Some shareholders
are merely holding onto their core position which now costs them nothing for the long haul and the next super spike which could drive the price much higher based upon positive phase one trial results coming in July for Oral B Amphotericin.
Is it a mistake to think that 54 million shares were purchased at prices over 14.4 cents, because for every seller there is a buyer?
If this is correct, then 14.4 cents ought to be the brand new base of support, but we closed below that today. Undervalued given what's in the pipeline!
<< Previous
Bullboard Posts
Next >>